Introduction
This review is meant to help providers stay abreast of the latest research, information, and recommendations regarding the vaccines included in the 2010 childhood and adolescent immunization schedules. Essential vaccine information, such as safety and vaccine effectiveness, is explored and confirmed by much of the research included in this review. Provider confidence in and recommendation of vaccines to patients are fundamental to vaccine uptake. Recent infectious disease outbreaks have resolved quickly, most likely due to a strong public health response and high vaccine coverage, despite the role of vaccine failures, unvaccinated persons, and close contact. Vaccine use should continue to expand as recommendations broaden [e.g., tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) and meningococcal vaccines], booster or additional doses are recommended, consensus on maternal vaccination grows, and the utility is proven for more subpopulations [e.g., men for human papilloma virus (HPV) or persons who are HIV-positive, egg allergic, or have inflammatory bowel disease (IBD)].
Influenza
Influenza infection causes widespread morbidity and mortality each season. Recent data from the Centers for Disease Control and Prevention show a range of 3349 to 48 614 influenza-associated deaths for the seasons between 1976 and 2007 [1] . The wide range in annual mortality reflects the variable virulence of circulating strains and fluctuating population immunity; these two factors were particularly evident during the 2009 influenza A (H1N1) pandemic when there were almost four times more pediatric deaths than ever recorded in a season.
Influenza vaccine continues to be the best way to prevent and control influenza. Vaccine is available in two forms, live-attenuated influenza vaccine (LAIV) administered via nasal spray or trivalent inactivated influenza vaccine (TIV) administered via injection. Both vaccine types offer significant protection against influenza; however, LAIV was shown to have a higher vaccine effectiveness when circulating strains do not match vaccine virus [2, 3] .
Further studies are needed to determine whether the difference in vaccine effectiveness is significant enough to favor one preparation over the other for children for whom either vaccine can be used. LAIV is currently approved for children and nonpregnant adults between the ages of 2 and 49 who do not have a history of wheezing and do not have an underlying disorder that increases the risk for influenza complications.
Febrile seizures
During the 2010 influenza season in the Southern Hemisphere, a CSL Biotherapies seasonal influenza TIV product was correlated with increased frequency of fever and febrile seizures in children aged 6 months through 4 years of age and an increased frequency of fever in children 5 through 8 years of age. As a result, an equivalent CSLmanufactured vaccine, Afluria, was not recommended for children 6 months through 8 years of age by the Advisory Committee on Immunization Practices (ACIP) this past influenza season [4] .
The Vaccine Adverse Event Reporting System (VAERS) received an increase in reports of febrile seizures in children vaccinated with Fluzone, a TIV manufactured by Sanofi pasteur and the only recommended vaccine for children 6-23 months of age in the United States during the 2010-2011 influenza season [5] . According to the most recent information available, there have been 53 VAERS reports of confirmed febrile seizures in children younger than 5 years of age, 42 of which occurred following the administration of Fluzone TIV in children 6 through 23 months of age. The children in all 42 cases fully recovered and 76% of these cases were nonserious. At this time, the cause of this increase in febrile seizures is unclear. Increased reporting could be related to awareness and concern over the events during the Southern Hemisphere influenza season. The recommendations for the use of influenza vaccine have not been changed as a result of the VAERS reports. Febrile seizures are relatively common in young children and can occur anytime a child has a fever. Following a febrile seizure, children almost always quickly and fully recover.
Vaccine uptake
Coverage rates for the 2009-2010 season (August 2009 through May 2010) based on the Behavioral Risk Factor Surveillance System (BRFSS) and the National 2009 H1N1 Flu Survey (NHFS) show a marked increase from previous years [6] . The coverage for ACIP recommended H1N1 vaccine target groups, which included pregnant women, healthcare personnel (HCP), children and young adults aged 6 months through 24 years, and persons aged 25 through 64 years who have medical conditions that put them at higher risk for influenza-related complication, was 34.2%. The national rates for coverage of children aged 6 months through 17 years of age for seasonal influenza vaccination and for 2009 H1N1 monovalent vaccine were 43.7 and 40.5%, respectively. Data gathered from eight immunization information system sentinel sites, reported by providers, gave a seasonal vaccine coverage rate of 26.3% for one or more vaccine doses for children 6 months through 18 years of age [7] . These data also showed that improvements varied by age group. Children 6-23 months of age who had at least one seasonal influenza vaccine dose showed only a 0.5% increase (55.2-55.7%) in coverage from the [2008] [2009] season to the 2009-2010 season. Coverage for children 2 through 4 years of age improved from 33% coverage to 38.4%, whereas coverage for children 5 through 12 years of age increased from 19 to 27.1% and adolescents aged 13 through 18 years of age showed an increase from 10.9 to 15.3%. The full vaccination coverage rate showed increases but overall remained low, at 22.5%, for children 6 months through 18 years of age.
Close examination of the attitudes and behaviors from the 2009-2010 season can inform future immunization interventions and allow continued increases in influenza vaccine coverage. Poland reported that common barriers to vaccination included concerns over the safety of a new vaccine product and the perception that risk of infection or complications was very low [8 ] . During the 2009 influenza A (H1N1) pandemic, there was a strong global correlation between receipt of H1N1 monovalent vaccine and prior receipt of seasonal influenza vaccine. Uptake of vaccine was also far more likely when information about vaccine was received from HCP, when the HCP served as role models by receiving vaccine themselves, and when Update on childhood and adolescent immunizations Lai et al. 471
Key points
Perception of risk and concerns over vaccine safety were major barriers to immunization during the 2009 H1N1 pandemic, which will be addressed in the future by providers. Parental attitudes toward immunization, international travel, waning immunity, and close contact are factors in recent measles and mumps outbreaks among highly vaccinated populations. Measles, mumps, rubella, and varicella combination vaccine is associated with a two-fold increase in febrile seizures when compared with separate administration of MMR and varicella vaccines. Ten-year follow-up on hepatitis A vaccine administration has shown strong immunogenicity and antibody persistence.
Recommendations have expanded the use of quadrivalent human papillomavirus vaccine and tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine.
the safety and benefits of the vaccine were publicized throughout the season.
Contributing to a growing consensus, the American Academy of Pediatrics (AAP) recommended annual mandatory influenza immunization for HCP in an October 2010 policy statement [9] . A longstanding recommendation and voluntary programs for influenza immunization have not led to achievement of the Healthy People 2010 coverage goal among HCP. HCP-related transmission of influenza has been reported in multiple healthcare settings. A mandatory program is described as ethically justified, necessary to achieve herd immunity, and long overdue. Additionally, mandatory programs have proven effective, have been instituted in the past (in schools or with tuberculin tests in healthcare settings), and are needed to protect the health and safety of patients.
BRFSS data also showed that, during the last influenza season, 56% of children with self-reported influenza-like illness (ILI) (fever with cough or sore throat in the past 30 days) were brought to healthcare providers [10] . HCP can offer influenza education -and influenza vaccine -to the large number of families seeking medical care for ILI. Vaccine should be offered even if influenza is circulating or has circulated in a community. Late-season influenza vaccination is another strategy to improve coverage and reduce a community's influenza burden. Suh et al. [11] found that 29% of physicians stop influenza vaccination by January and 36% stop in February. In seasons with vaccine shortage, nearly half of participating physicians reported vaccinating into March. This study reflects the willingness of physicians to vaccinate late into the influenza season, but does not indicate the volume of patients to whom physicians offer late-season vaccination. ACIP and AAP recommend offering influenza vaccine through March, even into May. Major barriers to late-season vaccination included the financial burden of leftover supplies, extra staff, and high patient volume during the winter. On the other hand, continuing to offer the vaccine will increase the likelihood of providing the second dose for those children less than 9 years of age who need two doses of influenza vaccine.
School-based influenza immunization
School-aged children represent a particularly important demographic for influenza vaccine intervention. In close contact on a regular basis with one another, they carry a large disease burden through transmission at school, often introducing influenza to family members and other household contacts. Schools also offer an alternative location to the physician's office for influenza vaccination. providers and certain racial backgrounds showed higher rates of vaccine coverage during the prenatal period; of particular importance, these differences in coverage rates were no longer apparent after delivery, suggesting an equalizing effect of a hospital-based intervention. Cocooning through immunization of household contacts as well as vaccinating pregnant women are two significant forms of protection for infants under 6 months of age for whom there is no licensed influenza vaccine. This age group is at high risk of influenza complications.
Maternal immunization
Eick et al. [15] conducted a study over three influenza seasons to examine the benefits in the first months of life for children born to mothers immunized against influenza. Infants born to immunized mothers showed a 41% reduction in the risk of laboratory-confirmed influenza virus infection and a significant reduction in the severity of illness if a child experienced ILI. This population also showed significantly higher hemagglutinin inhibition antibody titers at 2-3 months of age, but this persisted at 6 months of age for only two out of the eight tested viral strains. No significant difference was found for vaccination in trimester two versus trimester three.
Independently of the benefit of maternal influenza immunization to the newborn, pregnant women are at greater risk for influenza-related complications and should receive vaccine for their own health and safety. Data from Pregnancy Risk Assessment Monitoring System (PRAMS) from 10 states revealed higher coverage levels during 2009-2010 than in the past [16] . The greatest concern for women who did not receive influenza vaccines was safety for their baby and themselves, misconceptions which can and should be addressed by HCP.
Egg allergic populations
Viruses for the LAIV and TIV are grown in eggs. In the past, influenza vaccine has not been recommended for egg allergic individuals. However, over the course of this year, growing evidence suggested that most egg allergic persons could receive TIV safely with fewer precautions than previously recommended. Chung et al. [17] examined the impact of skin testing on the outcomes of pediatric influenza vaccine recipients with egg allergy but no history of anaphylaxis. In the vaccine skin test group, 94.6% tolerated the vaccine without serious adverse reaction (78.6% tolerated without any localized or systemic reaction). Likewise, 96.5% of the group who bypassed skin testing did not experience any serious adverse reaction (79.1% tolerated without any localized or systemic reaction). All groups, including those who tested positive for skin reactions, experienced localized and systemic reactions at the same rate.
The American Academy of Allergy Asthma and Immunology (AAAAI) released a statement reflecting this latest evidence (skin testing is no longer recommended) and endorsing the regular vaccination of most egg allergic individuals [18] . Two methods have been recommended for administering TIV, with no reason to favor either method at this time.
(1) A two-step graded challenge. Administer one-tenth of the vaccine dose and observe the recipient for 30 min (standard observation time for receiving subcutaneous immunotherapy). If no symptoms emerge, administer the remaining nine-tenths followed by a second 30-min observation period. Booster doses can be administered in a single dose. (2) A single, age-appropriate dose. Administer the vaccine as indicated followed by 30 min of observation.
Resuscitative equipment should be available in the office. If the recipient shows any reaction to the vaccine, stop administering it and have her or him consult an allergist. For children who need a booster, the same product brand should be used, but the second dose does not need to be from the same lot as the first dose.
Vaccines with the lowest ovalbumin content should be used, even though it is unclear whether ovalbumin is the cause of allergic reaction. Prior data indicate that vaccine with less than 1.2 mg/ml is well tolerated. Ovalbumin content is available in the AAAAI statement or in vaccine package inserts.
These recommendations do not apply to individuals with a history of severe reactions. Many, if not most, of these individuals have tolerated influenza vaccine well, but potential recipients should consult with an allergist until clear recommendations are established. These updated recommendations will expand the number of individuals who can receive protection against and help control the spread of influenza virus, a change in practice which is especially important in light of the 2009 influenza A (H1N1) pandemic.
Measles, mumps, and rubella vaccine
Coverage with one or more doses of measles, mumps, and rubella (MMR) vaccine among children 19 through 25 months of age dropped slightly from 2008 to 2009, from 92.1 to 90% [19] . The alleged link between MMR vaccine and autism continues to be a concern for some parents in spite of the vast amount of evidence that no association exists between the vaccine and autism or autism spectrum disorders. Mrozek-Budzyn et al. [20] conducted a study examining a Polish population of individuals who were unvaccinated, vaccinated with measles monovalent vaccine, and vaccinated with MMR vaccine, adding to the evidence. This study found no association between MMR vaccination or vaccination with measles monovalent vaccine and autism. Healthcare professionals must continue to educate each other and their patients on this matter.
Several recent measles and mumps outbreaks have drawn attention to the need for more information about MMR vaccine failure, waning immunity, and parental attitudes around vaccines.
In San Diego in 2008, an intentionally unvaccinated child exposed over 800 people after returning from Switzerland infected with measles. A study that examined this outbreak found that it cost approximately $10 000 per case (total of 12 cases, all unvaccinated children) to contain and that transmission was greatly assisted by vaccination refusal [21 ] . Parents of intentionally undervaccinated children were generally from privileged backgrounds (college education, upper or middle-income, white). They reported that both their concerns around vaccine safety, including concerns over autism spectrum disorders, and their support of a 'natural lifestyle' led them not to vaccinate their children. Importantly, these parents reported that their mainstream healthcare provider had supported their decision not to vaccinate. Concern over the safety of vaccines plays a key role in the reemergence of infectious disease outbreaks. This study highlighted the critical education physicians can provide, but may have failed to sufficiently perform in this case study.
The case in San Diego also underscores the function of international air travel in facilitating the spread of measles and the importance of vaccination prior to such travel. In July 2010, an unvaccinated child with laboratory confirmed measles was reported to be contagious during a flight from Switzerland to Massachusetts [22] . Later in July 2010, a traveler on this plane developed laboratory confirmed measles and exposed 270 international participants in an educational program who were able to either confirm their immunity or be quarantined.
A 2004 mumps outbreak in the Netherlands led Brockhoff et al. [23] to examine factors contributing to the spread of disease in a highly vaccinated population. An attack rate of 12% was found among vaccinated students at an international boarding school. No correlation was found between attack rate and age, so it appears that waning immunity was not the exclusive factor in the outbreak. Rather, the authors suggest that the combination of waning immunity, immunization status, and close contact (at a boarding school and at a 75th anniversary party for the school) may be responsible for such a high attack rate and vaccine failure.
A 2009 mumps outbreak also occurred in highly vaccinated populations in New York and New Jersey after an 11-year-old boy, the index case, returned from the United Kingdom, where over 7000 laboratory confirmed cases were documented that year [24] . The index case traveled to summer camp, infecting other participants and staff, who returned home where transmission continued. Over 1500 cases were reported by January 2010. This outbreak has mostly affected school-aged boys in a religious community with larger households. Among children and adolescents 7 through 18 years of age, who represented the vast majority (91%) of cases, 93% had received one dose of MMR vaccine and 85% had received two doses. Again, close direct contact appears to be a risk factor.
As in previously reported mumps outbreaks, these two occurred in highly immunized populations and most cases have been largely in vaccinated individuals. The mumps component in MMR appears to have a lower vaccine effectiveness than the other vaccine components. Dominquez et al. [25] utilized epidemiological data from the Navarre and Catalonia regions of Spain to find a vaccine effectiveness against mumps for two doses of MMR vaccine to be 88.5%, a value that is similar to or slightly lower than values presented by other researchers. Further research is needed to improve protection and determine the impact of booster doses. Mumps vaccine remains the single best public health strategy for prevention and containment of mumps virus.
Protection of infants against measles prior to immunization remains a challenge, particularly as fewer women have antibodies from natural immunity passed on to their newborns. A Belgium study compared the maternal antibodies in newborns for women vaccinated against measles and women with natural protection [26] . Cord blood for newborns with mothers who had been vaccinated had significantly lower geometric mean titers (GMTs) than newborns with mothers who were naturally immune (698 versus 2221 GMT in mIU/ml). Furthermore, the median time to loss of immunity was only 0.97 months for newborns of vaccinated women, but 3. Fiebelkorn et al. [27] found that the highest incidence of measles cases was among United States residents 6 through 11 months of age. Cocooning may offer the best protection until more data on earlier vaccine delivery and/or adult boosters become available. Infants 6 through 11 months of age should be given a dose of MMR vaccine during an outbreak, or if exposed to measles or in preparation for international travel. However, it is important to recognize that children who are vaccinated with MMR before 12 months will still need two doses of MMR at the regularly indicated ages.
In the postelimination era measles data, more than 80% of cases for both residents and foreign visitors were among unvaccinated persons or persons whose vaccination status was unknown. While measles continues to be imported through international travel, Fiebelkorn et al. found that outbreaks were quickly contained, most likely due to high vaccination coverage and vaccine effectiveness as well as aggressive public health responses. Two deaths were reported and 23% of cases resulted in hospitalization, underscoring the importance of measles prevention and containment.
Finally, efforts to eliminate rubella and congenital rubella syndrome (CRS) are improving worldwide [28] . Rubella usually does not have serious consequences for children and adults, but infection during pregnancy (CRS) can cause fetal death or birth defects. Since 2000, there has been an 82% reduction in the number of rubella cases reported by member states to the WHO. Between 1996 and 2009, the number of WHO member states including rubella-containing vaccines in national immunization schedules increased from 83 to 130 out of 193. Financial barriers thwart the inclusion of rubella in schedules for many of the remaining member states. However, lifetime costs for CRS cases are far more expensive than administering measles-rubella (MR) and MMR vaccines, and coverage with these vaccines will ideally increase rapidly in the near future.
Varicella
Two vaccines are licensed for the prevention of varicella in infants and children: a monovalent varicella vaccine and a quadrivalent [measles, mumps, rubella, and varicella (MMRV)] vaccine. Phase IV postlicensure data and Vaccine Safety Link data have shown that MMRV is associated with a two-fold increase in febrile seizures 7-10 days following vaccination of children 12-18 months of age when compared with MMR and varicella given separately [29 ] . This results in approximately one additional febrile seizure for every 2300 doses of MMRV given compared with MMR and varicella vaccine administered separately. A new Vaccine Information Statement for varicella vaccine has been created that contains information for parents on this association. Providers should explain the excess risk of febrile seizures for MMRV and families should be given the opportunity to express preference for the formulation of varicella vaccine to be given for the first dose. There is no evidence for an increased risk of febrile seizures for the second dose of MMRV, which is typically given at 4 through 6 years of age.
Varicella vaccine is effective for HIV-infected children, according to a recent study by Son et al. [30] . Vaccine effectiveness against varicella and herpes zoster was 82 and 100%, respectively, for this demographic. Highly active antiretroviral therapy receipt and immune system strength (CD4 cell percentages) were accounted for in measuring effectiveness.
Varicella coverage continues to be high, with 2009 estimates of 89.6% for one or more vaccine doses [31] . The ACIP recommended a routine two-dose varicella schedule in 2006 to reduce breakthrough varicella after one dose of vaccine, which occurred in about 15-20% of recipients. The Philadelphia Department of Public Health studied the impact of a second dose of varicella for outbreak control when a school with high one-dose coverage experienced a breakthrough outbreak [32] . A second dose for outbreak control was found to reduce varicella incidence by 76% for students who were exposed in the classroom. The students and staff who received a second dose of vaccine but still developed varicella experienced much milder symptoms. A twodose coverage rate of 65% was achieved with vaccines administered by primary care providers. For children who were not up to date when the outbreak occurred, this study showed that vaccination by providers during an outbreak is a feasible intervention for undervaccinated or unvaccinated children.
The effectiveness of the two-dose varicella series was also explored by Kattan et al. [34] . Varicella cases and varicella complications decreased during this time frame by 63 and 81%, respectively. Most varicella complications were dermatologic and included superinfections, phlegmon, and/or abscesses. Otitis media, neurologic complications, and pneumonia accounted for notable subsets of reported complications as well, but with less frequency. Most children who experienced complications were previously healthy and did not have an underlying condition. A study examining the impact of the National Immunisation Programme (NIP) in Australia found that congenital and neonatal varicella incidence was reduced by 100% and more than 85%, respectively, 3 years after public funding became available through NIP for vaccination [35] .
The effectiveness of varicella vaccine will reduce adult exposure to disease and, therefore, reduce immune boosting. A modeling study by Brisson et al. [36] predicts the impact of both one-dose and two-dose varicella schedules in Canada to include short-term increases in zoster cases. The study by Carville et al. [37] compared hospitalizations for varicella and zoster in Victoria, Australia from 1995 through 2007; they found that admissions for varicella decreased each year by 7% and admissions for zoster increased each year from 1998 through 2007 by 5%. Zoster cases began increasing 2 years before varicella vaccine was introduced into the private market in 2000, so reduced incidence of varicella is likely working in conjunction with other factors to impact zoster cases. This study did not account for multiple admissions for zoster, nor did it distinguish zoster cases among individuals with underlying conditions. More information is needed to determine the impact of varicella vaccine on zoster cases.
Hepatitis A vaccine
Hepatitis A virus (HAV) vaccination became commercially available in 1996. In 2006, the ACIP recommended routine administration of HAV to all children nationwide at 1 year of age and older [38] .
Two studies published in 2010 demonstrated the immunogenicity and persistence of antibody produced by the inactivated HAV vaccine. A long-term study by Bian et al. [39 ] confirms the long-term immunity of the two-dose inactivated HAV vaccine (Havrix) schedule. This study of 200 children in China found that, 1 month after two primary injections of inactivated vaccine given at 0 and 6 months, 100% of patients who were seronegative before vaccination became anti-HAV positive. In the 10-year follow-up for 110 seropositive individuals, 109 remained anti-HAV positive, a seropositivity rate of 99.09%. Based on serum antibody levels measured at 10 years postvaccination, a protective level of antibody is estimated to be maintained for at least 25 years. Based on this study, we can expect 100% successful primary immunization with persistence of protective antibody immunity.
A smaller study of 48 children who were followed for 10 years after two doses of inactivated HAV vaccination (Avaxim 80U, Sanofi pasteur) was performed in Buenos Aires, Argentina. A total of 99.1% of patients seroconverted after one dose of vaccine, and after the two doses 100% of recipients demonstrated seroconversion. After 10 years, persistence of anti-HAV antibodies was found in 97.9% of children [40] .
Radzikowski et al. [41] published a study evaluating the immunogenicity of inactivated HAV in patients with IBD compared with healthy controls. A total of 134 individuals (66 patients and 68 controls) were included in the study. Although the rate of seroconversion was statistically lower in the IBD group compared with the control group when measured after the first dose of HAV, there was no significant difference in the rate of seroconversion after two doses (97 versus 100%, P ¼ 0.2407). Steroid treatment reduced achievement of seroconversion more than seven-fold at 4 weeks after the second dose of HAV vaccine; however, this reduction was transient and was not observed at the end of the study. Azathioprine and 6-mercaptopurine did not influence seroconversion rates. HAV is, therefore, immunogenic and safe in children and adolescents with IBD. IBD patients should receive inactivated HAV irrespective of their treatment.
Meningococcal conjugate vaccine
Meningococcal vaccine coverage continues to improve, but coverage rates remain low. The 2009 National Immunization Survey-Teen (NIS-Teen) found a meningococcal vaccine coverage rate of 53.6% among adolescents 13 through 17 years of age [42] . This represents an overall 11.8% increase from 2008. State and local coverage rates ranged from 19.3% in Mississippi to 78.3% in District of Columbia. According to the survey, no apparent difference in coverage was found between racial or ethnic groups or based on poverty status. For the 2009-2010 school year, seven states required meningococcal immunization. Providers should be offering meningococcal vaccine whenever indicated to improve coverage, regardless of mandate. Seroprotection is particularly important for adolescents aged 16 through 21 (the age group at the highest risk of disease), freshmen entering college, persons with certain conditions which increase the risk for invasive disease, and travelers to areas where disease is hyperendemic.
Menveo (Novartis Vaccines and Diagnostics, Inc., USA) and Menactra (Sanofi pasteur, Swiftwater, PA, USA) are the two approved quadrivalent (serogroups A, C, Y, and W-135) meningococcal conjugate vaccines for use in persons 2 through 54 years of age. In October 2010, ACIP approved new recommendations for the use of the quadrivalent vaccines. Routine administration of meningococcal vaccine is recommended at 11-12 years of age followed by a booster dose at 16 years of age [43] . The recommendation for a booster dose was made based on observed duration of bactericidal antibody persistence postimmunization with conjugate meningococcal vaccine. Either vaccine can also be used for someone within the approved age range at greater risk of infection because of a persistent complement component deficiency, functional or anatomic asplenia, HIV infection, or a prolonged increased risk for exposure, such as travelers to hyperendemic or epidemic areas. A two-dose primary series (2 months apart) is recommended for persons with a persistent complement component deficiency, functional or anatomic asplenia or HIV infection. Booster doses are required every 5 years in people who remain at risk. A study by Gill et al. [44] looking at the extent of the immune response 22 months after administration found nonsuperiority of Menactra over Menveo when measuring the proportion of recipients with seroresponse. It was shown that Menveo had higher titers for serogroups A, W-135, and Y than Menactra at both 1 month and 22 months after vaccination. This evidence does not confirm better protection by Menveo than Menactra and no preference for one vaccine over the other is needed.
Both Tdap vaccine and meningococcal vaccine are part of the routine immunization schedule for adolescents 11-12 years of age. Both vaccines contain diphtheria toxoid and concerns have been raised over the potential for increased adverse events. A recent phase IV study examined the immunogenicity and safety of co-administration of the Tdap vaccine Boostrix (GlaxoSmithKline) and Menactra (MCV4) [45] . Co-administration was compared with both Tdap administration 1 month following MCV4 and MCV4 administration 1 month following Tdap. Although co-administration is recommended to increase compliance, all three modes of delivery offer satisfactory safety and immunogenicity.
School or daycare immunization requirements may bring children and adolescents into the pediatrician's office, offering another opportunity to increase compliance with the routine immunization schedule. The potential for improved coverage rates was highlighted in a study that examined the effect of a Tdap vaccination requirement on both Tdap and MCV4 vaccine coverage [46 ] . Although the MCV4 immunization coverage increased from the premandate period (10% coverage) for both the first (30%) and second year of the mandate (60%), coverage lagged significantly behind Tdap and co-administration levels remained low. Thus, although providers followed the mandate for Tdap vaccine, an effort was not made to provide all vaccines indicated for age. Providers should be familiar with patients' vaccine records and coadminister all age-appropriate vaccines, required at every patient visit.
Human papillomavirus vaccines (HPV4, HPV2)
There are two HPV vaccines available. The newer, bivalent vaccine, HPV2 (Cervarix; GSK), is approved for use in females 10 through 25 years of age and provides protection against HPV 16 and HPV 18, the two oncogenic types responsible for about 70% of cervical cancers [47] .
HPV4 (Gardasil; Merck & Co. Inc., West Point, PA, USA) was approved in 2006 for use in females 9 through 26 years of age and provides protection against HPV 16 and 18 as well as HPV 6 and 11. The latter two types are responsible for about 90% of genital warts. Recommendations for HPV4 have recently been expanded to include permissive use in males 9 through 26 years of age for the prevention of genital warts [48] . HPV4 use in males was recommended for the Vaccines For Children Program, even though it is not part of male adolescents' routine schedule. In November 2010, the Food and Drug Administration (FDA) approved HPV4 for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females 9 through 26 years of age. The ACIP is reviewing the data on which this licensure was based.
A study published in the New England Journal of Medicine reported HPV4 efficacy against extragenital lesions from HPV 6, 11, 16, and 18 to be 65.5 and 60.2% against lesions of any HPV type in a group of men who may or may not have been seropositive upon enrollment [49 ] . Efficacy against condylomata acuminata was 89.4% in a group of men who tested seronegative on day 1 and PCR-negative for the 7 months thereafter. Although these reported efficacies in men are lower than that in women, confidence intervals overlap and the vaccine may have a similar effect for both populations. The ACIP's recommendation for permissive use in males relies on providers' judgment in administering HPV4. There are a number of different factors to consider, some of which were addressed in a Gynecologic Oncology review article [50] . According to this review, over 65% of parents endorsed HPV vaccination for their sons. Acceptance of HPV vaccination among US males varied from 40 to 70%, with one study finding much greater willingness reported among men who have sex with men and bisexual men than among heterosexual men. Among HCP, nurses showed no effect of gender on willingness to vaccinate, but physicians felt more strongly about vaccinating females. Consistently with other literature, physicians also reported being more willing to vaccinate adolescents at an older age. Although finances and decreasing use of healthcare for men are noted as challenges to vaccination, arguments to vaccinate include protection of men who have sex with men; protection of women by immunizing their male partners; equitable distribution of the vaccine burden as both men and women contribute to transmission; improved coverage rates because vaccination of males may be more culturally acceptable; and decreased costs from genital warts and HPV-related cancers in men. Although it has been found to be more cost-effective to immunize women than both women and men, modeling data indicate that, when vaccine uptake remains so low for women, the cost-effectiveness of immunizing men improves.
HPV vaccination coverage is improving but at a slower rate than most newly introduced vaccines. The 2009 NISTeen data revealed that coverage with one or more doses of HPV vaccine was 44.3, and 26.7% for all three doses [43] . In 2008, these figures were 37.2% for one or more doses and 17.9% for all three doses. Adherence to the vaccine schedule is mixed. Most disconcertingly, the very demographics (racial minorities, low-income girls and women) suffering the greatest proportion of cervical cancer also appear to have the hardest time getting fully vaccinated. Ideally, girls and women receive their second dose 1-2 months after the first and their third dose 6 months after the first.
A survey administered to a national network of physicians found that almost all pediatricians (98%) and most family physicians (88%) are administering HPV vaccine [51] . Physicians reported being more likely to strongly recommend the vaccine to older adolescents. For example, 56% of pediatricians strongly recommend HPV vaccine to 11-year and 12-year-olds as opposed to 90% for 13-year through 15-year-olds and 94% for 16-year through 18-year-olds. In addition, most physicians were not using specific methods to have patients return for their second and third doses. One strategy involves offering vaccine with other adolescent health needs.
Widdice et al. [52] looked at the actual vaccine schedule for women 9 through 26 years of age and found that 14.3% of those who initiated vaccination completed by 7 months and 27.7% completed by 12 months. Women who identified as black were less likely to complete the series in either the 7-month or 12-month time frame than women who identified as white. Interestingly, women receiving Depo-Provera (Depot Medroxyprogesterone Acetate, DMPA), an injectable form of birth control administered every 3 months, completed the series at a higher rate. The improvements in coverage among women receiving DMPA highlight the improved compliance when patients have routine scheduled visits for recurring therapy. Low coverage among other patients illustrates the need for greater recall efforts for women for their second and third doses and the reduction of missed opportunities for administration (such as at urgent care visits that fall within the dosing schedule).
Notable differences in vaccination coverage have been found in a variety of medical settings. Only 9.4% of Medicaid-enrolled young women aged 11 through 18 had one or more doses of HPV vaccine and a mere 1.8% had received all three doses [53] . African-American girls were half as likely to complete the series and the least likely of all racial and ethnic groups to initiate vaccination. A major managed care system was able to address financial barriers by offering HPV vaccines to women at only the cost of a co-pay. Chao et al. [54] conducted a study examining women aged 9 through 26 with memberships at this system and found that racial/ ethnic minorities, lower neighborhood income level, having a male primary care provider, and a history of hospitalization were correlated with lower odds of HPV vaccination. Conversely, factors such as enrollment in state-subsidized programs, having a pediatrician as a primary care provider, a history of influenza vaccination, and having women's health or immune health-related conditions correlated with greater chances of HPV vaccination.
Pruitt and Schootman [55] examined vaccine uptake among 13-year through 17-year-olds in six states. Using BRFSS data, it was found that young women from states with higher levels of poverty were less likely to have received the vaccine. However, it was also reported that greater poverty at a county level was associated with better rates of vaccination; this may be because a larger portion of funding for public programs is allocated to these areas and perhaps reflects the success of such programs. Although the literature is mixed, this study also found that young women from less educated households were less likely to be vaccinated. This study found no racial or ethnic disparities and also reported better odds of vaccination with older age, underscoring the need for providers to do outreach for low-income and younger women.
HPV vaccination is influenced by parental attitudes and parent-child relationships. One study that focused primarily on a Latino population, the fastest growing subset in the United States, found that 97% of parents who vaccinated their daughters identified prevention of cervical cancer as the reason [56] . The majority (55%) of parents who did not vaccinate their child identified the need for more information and very few (8%) cited fears of increased sexual activity as their reason to withhold vaccine. Parents also listed the physician not offering the vaccine (21%) as a reason for not vaccinating. Both the lack of information and the failure to have the vaccine recommended are major barriers that can be readily addressed by providers. [60] . More than half of the resources used for the outbreak were spent during an intensive 10-day period. Each case cost approximately $2172 and required 42 regular person hours and 1 overtime hour. This cost analysis emphasizes the need to develop a clear protocol and targeted chemoprophylaxis campaigns following a reported pertussis case, particularly as pertussis cases continue to rise.
A total of 16 858 cases of pertussis and 12 infant deaths were reported in 2009. In an effort to curb these outbreaks and protect infants who cannot yet receive direct protection, the ACIP updated its recommendations for the use of Tdap vaccine in October 2010 [61] . These recommendations made changes to the interval of use and the age groups for administration. Specifically, Tdap can now be given without regard for the last time (if known) an individual received a tetanus toxoid or diphtheria toxoid-containing vaccine. Longer intervals are correlated with lower rates of local reactions, but guidance for use emphasizes the benefits of immunization over the potential for adverse events. Persons 65 years of age and older who have not received a Tdap vaccine and will or may have close contact with an infant 12 months of age or younger should now be administered one dose of Tdap. Finally, children 7 through 10 years of age who are not fully vaccinated (i.e., have not received a total of five doses of DTaP or four doses if the fourth dose was administered on or after the recipient's fourth birthday) should be administered one dose of Tdap. Either licensed Tdap vaccine can be used for these additional age groups.
'Cocooning' is another strategy that can be utilized to protect infants against pertussis. Most infants (75%) are infected with pertussis by household members or close contacts, so immunization of these populations has been recommended to reduce the risk of transmission. One study implemented Tdap cocooning in two phases at a public hospital in Texas: maternal postpartum vaccination and targeted vaccination on site for household contacts of newborns [62 ] . Over 90% of postpartum women participating in the study were vaccinated. Vaccine coverage improved when the 2-year minimum between previous tetanus-containing vaccines was eliminated. Furthermore, the median number of household contacts was three and the median number of vaccinated contacts was two. Through this cocooning program, about 58% of interviewed mothers reported that more than one household contact (other than the mother) was vaccinated. It takes approximately 14 days for vaccine recipients to develop a protective immune response, and newborns are still at risk for pertussis exposure during that time. Therefore, vaccination of household contacts before delivery is ideal. However, this study noted that a wider range of those contacts are more likely to visit and accept the vaccine at the hospital rather than at other healthcare sites, like the pediatrician's office.
Maternal immunization with Tdap is the only other method for protecting infants against pertussis. Gall et al. [63] compared newborn serum antibody levels in infants born to women who had received the Tdap vaccine during pregnancy and women who had not. Tetanus toxoid (TT) and diphtheria toxoid (DT) antibodies and specific pertussis antibodies, pertactin (PRN), pertussis toxin, filamentous hemagglutinin (FHA), and fimbriae (FIM) 2/3 were measured and found to be significantly higher in newborns born to mothers immunized during pregnancy. Odds improvement for protection against disease increased 11 times for pertussis toxin, nine times for FIM, and six times for diphtheria. Tetanus, FHA, and PRN disease protection were not significantly improved for newborns born to mothers immunized during pregnancy. The ACIP recommends that Tdap immunization of pregnant women be deferred until delivery, but the AAP endorses Tdap immunization of pregnant adolescents. Either method can be used. The ACIP recommendation considers the possibility that there may be interference between passive and active immunization for newborns. This study shows that immunization during pregnancy may offer some protection during the period of highest risk for infants.
The potential for local reactions at the DTaP injection site rises with the number of doses. A study by Jackson et al. [64] using Vaccine Safety Datalink compared vaccination in the arm versus the thigh for the fifth DTaP dose. The study found that arm injection has a 78% higher rate of local reaction. However, almost 14% of children who had a medically attended local reaction following DTaP injection in the thigh had trouble walking. Although the thigh offers a reasonable alternative to arm injection, the arm is still preferred and recommended for mobility.
Mild adverse events, such as local reactions, are relatively common with DTaP administration, but acellular pertussis vaccine has had far fewer serious side-effects compared with diphtheria, tetanus and pertussis (DTP) (which included whole-cell pertussis vaccine). The lack of association between DTaP vaccine and seizures was documented in a study by Huang et al. [65] involving 433 654 children using Vaccine Safety Datalink data.
Conclusion
This review has covered the latest research on the childhood and adolescent vaccines, which are part of the annual harmonized immunization schedules of the Centers for Disease Control and Prevention (CDC), AAP, and the American Academy of Family Practice (AAFP). Vaccine administration continues to be the most effective public health strategy to prevent and control infectious diseases. HCP play a critical role by providing vaccine education, recommending vaccines, and serving as examples by receiving recommended vaccines for themselves.
